Abstract:Key PointsCNS remyelination is the regenerative process by which myelin sheaths are restored to demyelinated axons. Unlike the poor regeneration that occurs following neuronal injury, remyelination can occur as a spontaneous and efficient process in experimental models and many clinical conditions.Although remyelination can occur in multiple sclerosis (MS; a widely occurring demyelinating disease), it often fails, leaving axons demyelinated and vulnerable to degeneration. Recent studies have revealed the importance of the myelin sheath for maintaining axonal integrity and hence the importance of promoting remyelination in diseases such as MS as an effective means of neuroprotection.Remyelination is mediated by a population of adult neural stem cells that are widely distributed throughout the CNS and that are commonly referred to as oligodendrocyte precursor cells (OPCs). These cells respond to demyelination by activation, proliferation, migration and finally differentiation into remyelinating oligodendrocytes; it is the last of these processes that is most likely to fail in MS and leave areas of demyelination containing oligodendrocyte-lineage cells that are unable to fully differentiate.Remyelination is governed by a complex interaction of environmental signals and cell-intrinsic mechanisms that are triggered by the inflammatory response to injury. This response therefore has a key role in initiating remyelination. The network of signals that is involved in remyelination shows high levels of redundancy.In theory, remyelination can be enhanced either by promoting endogenous remyelination or by transplanting myelinating cells. The first approach, which may have a pharmacological basis, is especially attractive for diseases such as MS in which remyelination occurs and will involve either the antagonism of negative regulatory pathways and/or the enhancement of positive regulatory pathways.Cell therapy (transplantation) approaches to remyelination are expected to be of particular benefit for genetic demyelinating diseases in which there is an inherent defect in the oligodendrocyte lineage. Recent studies have provided proof-of-principle that human cells can be used to remyelinate the entire CNS in laboratory animal models.

Regenerative Capacity of Macrophages for Remyelination

M2 Microglia and Macrophages Drive Oligodendrocyte Differentiation During CNS Remyelination

Remyelination in the CNS: from biology to therapy

[Neuroscience] Remyelination in the Central Nervous System

Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination

Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches

Niacin-mediated rejuvenation of macrophage/microglia enhances remyelination of the aging central nervous system

Remyelination reporter reveals prolonged refinement of spontaneously regenerated myelin

Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination

Accelerated Remyelination During Inflammatory Demyelination Prevents Axonal Loss and Improves Functional Recovery

Cell-based remyelinating therapy in inflammatory demyelinating injury of the CNS

Promoting peripheral myelin repair

Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings

Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis

Rejuvenation of Regeneration in the Aging Central Nervous System.

Microglia: origins, homeostasis, and roles in myelin repair

Preventing production of new oligodendrocytes impairs remyelination and sustains behavioural deficits after demyelination

[Mechanisms Underlying Remyelination with Special Focus on Demyelination Models of Multiple Sclerosis].

Incomplete remyelination via endogenous or therapeutically enhanced oligodendrogenesis is sufficient to recover visual cortical function

Regulatory T cells promote myelin regeneration in the central nervous system

Remyelination protects neurons from DLK-mediated neurodegeneration